Skip to main content
. Author manuscript; available in PMC: 2011 Apr 12.
Published in final edited form as: Clin Cancer Res. 2008 May 15;14(10):3077–3082. doi: 10.1158/1078-0432.CCR-07-4743

Fig. 2.

Fig. 2

A, comparison of DFS for patients with secondary AML who received two-cycle timed sequential therapy with (12 patients; dotted line) and without (12 patients; solid line) tipifarnib maintenance therapy. B, comparison of DFS for patients with adverse cytogenetics who received two-cycle timed sequential therapy with (15 patients; dotted line) and without (14 patients; solid line) tipifarnib maintenance therapy.